PHGE

Biomx Inc

Add to Watchlist

Advanced Chart

0.540

-0.008(-1.460%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.555

Open

0.5519

VWAP

0.54

Vol

128.66K

Mkt Cap

14.32M

Low

0.5233

Amount

69.45K

EV/EBITDA(TTM)

Total Shares

69.81M

18.73M

EV/OCF(TTM)

P/S(TTM)

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

1 Analyst Rating

Wall Street analysts forecast PHGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHGE is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.540

Low

15.00

Averages

15.00

High

15.00

Current: 0.540

Low

15.00

Averages

15.00

High

15.00

H.C. Wainwright

Joseph Pantginis

Buy

downgrade

$21 -> $15

2025-05-16

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$21 -> $15

2025-05-16

downgrade

Buy

Reason

H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on BiomX to $15 from $21 and keeps a Buy rating on the shares following the Q1 report.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$21

2025-04-04

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$21

2025-04-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$2 → $21

2025-04-01

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$2 → $21

2025-04-01

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-01-10

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-01-10

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

2025-01-08

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-01-08

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Biomx Inc (PHGE.A) is -0.44, compared to its 5-year average forward P/E of -1.69. For a more detailed relative valuation and DCF analysis to assess Biomx Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.69

Current PE

-0.44

Overvalued PE

-0.13

Undervalued PE

-3.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.63

Current EV/EBITDA

-0.70

Overvalued EV/EBITDA

0.39

Undervalued EV/EBITDA

-1.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

14.88

Current PS

0.00

Overvalued PS

64.95

Undervalued PS

-35.18